Skip to content
★ Sign in to follow
HB

H Barron

GlaxoSmithKline plc
Total declarations
86
Company
1
▲ Purchases (11 ops.)
€175k
▼ Sales (0 ops.)
—

Latest filing published 01 Mar 2022 for GlaxoSmithKline plc, €3,279.

Filing timeline

BuySale
H Barron

Insider track record

Disclosed buys
11
Disclosed sells
0
Signal history

Closed purchases

Market purchases
11

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

H Barron: trading record in brief

All filings by H Barron on record concern GlaxoSmithKline plc. We count 86 filings; the first trade dates from 14 February 2018 and the latest from 24 February 2022.

Every open-market trade on record is a purchase: 11 purchases worth €175k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 75 share grants. So far in 2022, the count stands at 4 purchases and no sales.

The median purchase comes to €7,220.

Most recently, on 1 March 2022, the filings show a share grant worth €3,279 in GlaxoSmithKline plc. The most recent open-market purchase was published on 24 February 2022, 1,717 days ago. Typically, a trade is published a median of 2 days after it takes place. The regulation allows three business days to notify a trade (UK MAR). These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.

Companies and markets linked to H Barron

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations86 total
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    3,707 USD0FCA-NSM
    90 shares@ US$41.19New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4287165-0
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    135,212 USD0FCA-NSM
    3,282.633 shares@ US$41.19New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4287165-1
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    46,864 USD0FCA-NSM
    1,097.774 shares@ US$42.69New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4282952-0
  • ▲
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    8,410 USD0FCA-NSM
    197 shares@ US$42.69New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4282952-1
    Canonical exit: 23 May 2022 (T+90)
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    0FCA-NSM
    146,831 shares0N/AISIN US37733W1053FCA-NSM:4277167-2
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    3M USD0FCA-NSM
    79,172 shares@ US$43.3404New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4277167-3
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    0FCA-NSM
    43,266 shares0N/AISIN US37733W1053FCA-NSM:4275770-2
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    0FCA-NSM
    19,936 sharesN/AISIN US37733W1053FCA-NSM:4275770-3
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    2M USD0FCA-NSM
    40,617 shares@ US$42.87N/AISIN US37733W1053FCA-NSM:4275763-2
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    46,864 USD0FCA-NSM
    1,041.653 shares@ US$44.99New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4267092-0
  • ▲
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    8,413 USD0FCA-NSM
    187 shares@ US$44.99New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4267092-1
    Canonical exit: 8 May 2022 (T+90)
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    46,864 USD0FCA-NSM
    1,055.97 shares@ US$44.38New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4252882-0
  • ▲
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    8,388 USD0FCA-NSM
    189 shares@ US$44.38New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4252882-1
    Canonical exit: 24 Apr 2022 (T+90)
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    49,932 USD0FCA-NSM
    1,080.147 shares@ US$46.2266New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4246765-0
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    51,774 USD0FCA-NSM
    1,149 shares@ US$45.06New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4245272-2
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    45,499 USD0FCA-NSM
    1,037.605 shares@ US$43.85New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4236509-0
  • ▲
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    8,156 USD0FCA-NSM
    186 shares@ US$43.85New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4236509-1
    Canonical exit: 7 Apr 2022 (T+90)
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    50,008 USD0FCA-NSM
    1,153.319 shares@ US$43.36New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4221991
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    50,008 USD0FCA-NSM
    1,179.988 shares@ US$42.38New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4207177
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    50,008 USD0FCA-NSM
    1,211.138 shares@ US$41.29New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4190350
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    108,995 USD0FCA-NSM
    2,626.374 shares@ US$41.50New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4188482-0
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    2,698 USD0FCA-NSM
    65 shares@ US$41.50New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4188482-1
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    50,008 USD0FCA-NSM
    1,169.228 shares@ US$42.77New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4173948
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    50,008 USD0FCA-NSM
    1,257.428 shares@ US$39.77New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4158002
  • ◆
    Chief Scientific Officer and President, R&DExecutivesGlaxoSmithKline plc
    49,348 USD0FCA-NSM
    1,274.757 shares@ US$38.7117New York Stock Exchange (XNYS)ISIN US37733W1053FCA-NSM:4146115-0

25 of 86 declarations